CD40 and systemic lupus erythematosus: Although promising results with blockade of CD28 and CD40 in mouse models of SLE ameliorate disease and reduce the severity of disease indicators such as class-switched B cells and autoreactive-IgG, little efficacy was observed when targeting CD28, CD40, and ICOS in SLE patients (141–143).